Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Amgen and Cytokinetics begin omecamtiv mecarbil’s trial

Omecamtiv mecarbil is a selective cardiac myosin activator intended for heart failure patients with reduced ejection fraction. Credit: Bryan Brandenburg.

  • Amgen and Cytokinetics omecamtiv mecarbil trial

Go Top